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well known. Vanden Berghe and
Vandenabeele and colleagues predict
through comparative genomics (webtool)
that nearly all 129-derived genetically
modified congenic mice are affected by
multiple inactivating passenger
mutations despite intensive
backcrossing and illustrate phenotypic
interference through some case studies.
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Targeted mutagenesis in mice is a powerful tool for
functional analysis of genes. However, genetic varia-
tion between embryonic stem cells (ESCs) used for
targeting (previously almost exclusively 129-derived)
and recipient strains (often C57BL/6J) typically re-
sults in congenic mice in which the targeted gene is
flanked by ESC-derived passenger DNA potentially
containing mutations. Comparative genomic anal-
ysis of 129 and C57BL/6J mouse strains revealed in-
dels and single nucleotide polymorphisms resulting
in alternative or aberrant amino acid sequences in
1,084 genes in the 129-strain genome. Annotating
these passenger mutations to the reported geneti-
cally modified congenic mice that were generated
using 129-strain ESCs revealed that nearly all these
mice possess multiple passenger mutations poten-
tially influencing the phenotypic outcome. We illus-
trated this phenotypic interference of 129-derived
passenger mutations with several case studies and
developed a Me-PaMuFind-It web tool to estimate
the number and possible effect of passenger muta-
tions in transgenic mice of interest.
INTRODUCTION
The importance of the genetic background in the phenotype of
transgenic mice is well established (Gerlai, 1996; Simpson
et al., 1997). Until recently, genetically modified mice were
mostly created using germline transmission competent embry-
onic stem cells (ESC) lines derived from the 129 strain of mouse
(Simpson et al., 1997). For phenotypic studies, chimeric mice are
backcrossed repeatedly to a particular strain, often C57BL/6J
(Lusis et al., 2007). Although this strategy is commonly consid-
ered to omit ESC-derived genetic background effects, the region200 Immunity 43, 200–209, July 21, 2015 ª2015 Elsevier Inc.closely flanking the targeted gene remains of donor origin (pas-
senger genome) because the gene recombination frequency de-
creases near the targeted locus. The genetic variation between
donor and recipient strains implies that the passenger genome
typically contains mutations in the regions flanking the targeted
gene (passenger mutations). This might influence phenotypic
outcomes in genetically modified mice and cells derived thereof
(Lusis et al., 2007).
When mice are backcrossed for 10 generations to C57BL/6J
(certified as congenic mice; Flaherty, 1981) the probability that
a 1 centiMorgan (cM) region flanking each side of the targeted
gene is still of donor origin is 0.91 (Lusis et al., 2007). In congenic
mice, the linkage between a targeted gene and flanking donor
genes increasingly fades away from 10 cM onward (Lusis
et al., 2007). This problem has been clearly highlighted back in
the mid-nineties (Crawley et al., 1997; Gerlai, 1996; Simpson
et al., 1997). Although several reports identify 129-derived pro-
tein coding variants in for example DAP12 (Tyrobp) signaling
(McVicar et al., 2002), DNA polymerase iota (Poli) (McDonald
et al., 2003), beaded filament structural protein 2 (Bfsp2) (Aliza-
deh et al., 2004; Sandilands et al., 2004), disrupted-in-schizo-
phrenia (Disc1) (Go´mez-Sintes et al., 2014; Koike et al., 2006),
apolipoprotein A-II (Apoa2) (Su et al., 2009), oculocutaneous
albinism II (Oca2) (Rogers et al., 2012), and chromatin licensing
and DNA replication factor 1 (Cdt1) (Coulombe et al., 2013),
this issue has been generally ignored. This issue however
re-emerged when Casp1 null mice were found to carry an inac-
tivating passenger mutation in the neighboring Casp11 gene
(Kayagaki et al., 2011). Essentially, the strong protection
observed in Casp1 null mice against a lethal lipopolysaccharide
(LPS) challenge was found to be mainly due to this inactivating
passenger mutation in the Casp11 gene (Kayagaki et al., 2011).
This raised again the awareness of a potential phenotypic
effect of closely linked passenger mutations originating from
the 129-derived ESCs. This is unfortunately not an isolated
case, because other genetically modified mice are also affected
by this Casp11 passenger mutation such as Casp3- and Birc2
null mice (Kenneth et al., 2012; Vanden Berghe et al., 2013).
This prompted us to setup a comparative genomics analysis
between C57BL/6 and 129 strains and map these differences
to all genetically modified mice that origin from 129-strain
ESCs reported by the Mouse Genome Informatics (http://www.
informatics.jax.org/).
RESULTS
Comparative Genomics of the Reference Genome and
129 Strain Genomes
Toanalyze the impact of inactivatingpassengermutationson129
ESC-derived genetically modified mouse strains, we compared
the129 andC57BL/6J genomic sequences releasedbyTheWell-
come Trust Sanger Institute (Keane et al., 2011; Yalcin et al.,
2011). Filtering onpredicted protein sequence alterations yielded
949 indels and 446 single nucleotide polymorphisms (SNPs)
affecting1,084genes (FigureS1A).Note that thenumber of indels
and SNPs that affect protein sequence relative to the C57BL/6J
reference sequence in several other laboratory inbred strains
are similar to thenumber observed in the129strain,while a higher
number is observed in wild-derived inbred strains (Table S1). Of
these predicted protein sequence alterations in the 129 strain,
188 result in gained or lost STOP codon (13%); 875 result in
frameshift variants, in frame indels or coding sequence variants
(63%); and 332 splice donor or acceptor variants (24%).
Annotation of the 129-Derived Protein Coding Variants
to Genetically Modified Congenic Mice
Theprobability andnumber of passengermutations in genetically
modified congenic mice typically depends on the size of the
considered flanking region around the target gene (Figure 1A).
The international database resource for the laboratory mouse
‘‘Mouse Genome Informatics’’ (MGI) illustrates that within the
pool of genetically modified mice (anno January 2015): 58% are
systemically modified, 29% are reporter mice, and 13% are
conditionally modifiedmice (Figure 1B). Almost 8,000 genetically
modified mice (corresponds to 80%) of the total pool are derived
from 129 ESCs (Figure 1C). By annotating the found passenger
mutations to the 129-derived genetically modified mouse lines,
we found that 99.5% of these mouse lines are affected by a me-
dian number of 20 passenger mutations within a 10 cM flanking
region (Figures 1E and S1B). Decreasing the size of the region
flanking each side of the target gene to 5or 1 cM,which increases
theprobability to respectively 0.63 and0.91, reveals that still 97%
(Figure 1F) and 71% (Figure 1G) of the reported 129 ESC-derived
genetically modified congenic mice are affected by a median
number of 11 and 2 passenger mutations, respectively (Figures
S1C and S1D, Table S2). This implies that nearly all 129-derived
genetically modified congenic mice contain multiple passenger
mutations despite intensive backcrossing. Consequently, the
phenotypes observed in thesemicemight be due to flanking pas-
senger mutations rather than a defect in the targeted gene. Note
that 76% of these reported 129-derived genetically modified
congenic mice are affected by a passenger mutation that results
in a gained STOP codon (Table S2).
Annotation of the 129-Derived Casp11 Passenger
Mutation to Genetically Modified Congenic Mice
As a reference locus, we analyzed the recently identified
129-derived Casp11 inactivating passenger mutation. Thereare 294 genes located within a 10 cM region flanking each
side of the Casp11 gene. To date, 86 genetically modified
mouse lines (derived from 129 ESCs) are reported of which
the targeted gene resides within this Casp11 flanking
genomic region. This indicates that in addition to the re-
ported Casp1 (Kayagaki et al., 2011) and Birc2 null animals
(Kenneth et al., 2012), at least 84 other 129-derived geneti-
cally modified congenic mice could be carrying the reported
inactivating Casp11 mutation (Table S3), which consequently
would make them resistant to LPS-induced shock (Hagar
et al., 2013; Kayagaki et al., 2011; Vanden Berghe et al.,
2013; Wang et al., 1998). Casp12 flanks most closely to
Casp11, and therefore Casp12 null mice are expected to
carry this Casp11 inactivating passenger mutation, which
could explain their resistance to LPS-induced shock (Saleh
et al., 2006).
The 129-derived Casp11 Passenger Mutation
Confounds Phenotypic Interpretation of Genetically
Modified Congenic Mice Targeting Several Members of
the Matrix Metalloproteinase Family
We noticed that several MMP family members reside within <5
cM distance of Casp11 (Table S3). Considering that Mmp7-,
Mmp8-, and Mmp13 null mice are protected against LPS
lethality (Vandenbroucke et al., 2013; Vandenbroucke et al.,
2012; Vandenbroucke et al., 2014), we analyzed the contribu-
tion of the Casp11 inactivating passenger mutation in this
phenotype. The closest Mmp gene to Casp11 is Mmp13
(<1 cM). We found that the Mmp13 null mice (backcrossed
R10 generations to C57Bl/6) originating from Stephen M.
Krane’s lab and subsequently bred in our lab (C.L.,
Mmp13Cli/ mice) (Vandenbroucke et al., 2013) contain the
Casp11 mutation despite intensive backcrossing to C57BL/6
(Figures 2A and 2B). Moreover, the Mmp13Cli/ mice were
protected against death (Figure 2C) and hypothermia (Fig-
ure 2D) caused by S. enterica-derived LPS. The resistance to
LPS was similar as observed in Casp11 null mice (Figures 2G
and 2H). However, Mmp13 null mice from Stephen M. Krane’s
lab that were bred in E.B. Brown’s lab (Mmp13Ebb/ mice) lost
the Casp11 mutation due to extensive additional backcrossing
(Figures 2A and 2B). Essentially, theseMmp13Ebb/ mice were
not protected against a lethal LPS dose, as shown by survival
rates (Figure 2D) and body temperature (Figure 2E). Using a
sub lethal dose of LPS neither resulted in any protection in
these Mmp13Ebb/ mice (Figure S2A), while showing even
an increased hypothermic response (Figure S2B). A more
extended analysis in different MMP-deficient mice revealed a
significant association (p = 0.048, Fisher’s exact test) between
the presence of the Casp11 mutation and MMP-deficient mice
that reside on chromosome 9 (Figures S2C and 2D). Similarly,
analysis of LPS resistance of several MMP-deficient animals re-
vealed a significant association (p = 0.029, Fisher’s exact test)
between LPS-resistance and the presence of the mutated
Casp11 allele on chromosome 9 (Figures S2E–S2I). Taken
together, our data indicate a phenotypic interference of the
mutated Casp11 allele with several members of the MMP fam-
ily. That said, we do not exclude a possible role of MMPs in
septic shock, because specific MMP8 inhibitors and broad-
spectrum MMP inhibitors improve the outcome in models ofImmunity 43, 200–209, July 21, 2015 ª2015 Elsevier Inc. 201
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Figure 1. All Genetically Modified Congenic Mice Originating from 129 Strains Are Populated with Passenger Mutations Despite Intensive
Backcrossing to C57BL/6
(A) Schematic representation of the probability that the region flanking the gene targeted by transgenic approaches remains of donor origin (source of embryonic
stem cells). For a region of 1 cM flanking the targeted gene in mice that were backcrossed 10 times to C57BL/6, the probability that this region remains of donor
origin is 0.91 (Flaherty, 1981; Lusis et al., 2007). Flanking regions of 5 and 10 cM have 0.63 and 0.39 probability, respectively, of remaining donor origin.
(B) Analysis of the classification of genetically modified mice reported by Mouse Genome Informatics anno January 2015.
(C) Analysis of the strain of origin of systemically gene modified mice reported by Mouse Genome Informatics anno January 2015.
(D) Analysis of the source of genetically modified mice reported by Mouse Genome Informatics (situation on January 2015).
(E–G) Analysis of the number of 129-derived passenger mutations per genetically modified congenic mouse strain for a genomic region of 10, 5, or 1 cM flanking
both sides of the targeted allele based on sequences released by The Wellcome Trust Sanger Institute (Keane et al., 2011; Yalcin et al., 2011). All pie charts
indicate absolute and relative amounts.MGI, MouseGenome Informatics; IMPC, InternationalMouse Phenotyping Consortium. See also Figure S1 and Tables S1
and S2.
202 Immunity 43, 200–209, July 21, 2015 ª2015 Elsevier Inc.
AB E
G H
F
C D
Figure 2. Casp11 Inactivating Passenger Mutation Provides Mmp13 Null Mice Resistance to LPS-Induced Shock
(A) Electrophoresis-separated PCR fragments of the genomic DNA region flanking the 5-bp deletion in Casp11 gene inMmp13 null mice derived from C.L.’s lab
(Mmp13Cli/), which carry the Casp11 passenger mutation, or from E.B. Brown’s lab (Mmp13Ebb/), which have the wild-type Casp11 gene. Samples derived
from C57BL/6 and 129S7 strains were included as negative and positive controls, respectively.
(B) DNA-sequencing profiles of the genomic DNA region flanking the 5-bp deletion inCasp11 gene inMmp13Cli andMmp13Ebb null mice. C57BL/6 and 129 strains
were used as negative and positive controls, respectively, for the 5-bp deletion in Casp11.
(C and D) Survival and body temperature were analyzed in function of time after intraperitoneal injection of 17.5 mg kg-1 Salmonella enterica LPS inMmp13Cli/
mice (n = 18) and in matching wild-type control Mmp13Cli+/+ mice (n = 18). The combined results of two independent experiments are shown.
(E and F) Survival and body temperature were analyzed in function of time after intraperitoneal injection of 7 mg kg-1 S. enterica LPS inMmp13Ebb/mice (n = 9)
and matching wild-type control Mmp13Ebb+/+ mice (n = 9).
(G andH) Survival and body temperature were analyzed in function of time after i.p. injection of 7mg kg-1S. enterica LPS inCasp11 null mice (Casp11Vda/, n = 8)
andmatching wild-type controls (Casp11Vda+/+, n = 6). Error bars of body temperature represent SEM. **p < 0.01. Log rank (Mantel-Cox) test (C and D) and F-test
(E). See also Figure S2 and Table S3.sepsis (Vandenbroucke and Libert, 2014; Vanlaere and Libert,
2009).
Opposing Phenotypes in 129 and C57BL/6 ESC-Derived
Panx1 Null Mice after Lethal LPS Challenge
In addition to several MMP family members, the Pannexin 1
(Panx1) locus resides within a 4 cM distance from the Casp11
locus (Table S3). Conceptually, one could study the LPS suscep-
tibility of Panx1 null mice considering the following data: the
molecular interplay between the hemichannel Pannexin 1 and
the Nlrp3 inflammasome, the proposed role of Pannexin 1 in
delivery of LPS to the cytosol (Kanneganti et al., 2007), and the
LPS-resistance of Nlrp3 null mice (Mariathasan et al., 2006).
Indeed, Panx1 null mice generated using 129-derived ESCs
(backcrossed to C57BL/6 for 5 generations) originating fromV.I.S.’s lab (Panx1Vsh nullmice)were resistant todeath (Figure 3C)
and hypothermia (Figure 3D) caused by E. coli LPS. The resis-
tance to LPS was again similar as observed in Casp11 null mice
(Figures 3G and 3H). Importantly, Panx1Vsh null mice were also
affected by the Casp11 passenger mutation (Figures 3A and
3B). In contrast, Panx1 null mice generated in V. M. Dixit’s lab
from C57BL/6-derived ESCs (Panx1Vmd null mice) were not pro-
tected against death (Figure 3E) and hypothermia (Figure 3F)
caused by LPS, which is associated with the presence of a WT
allele for Casp11 (Figures 3A and 3B). In conclusion, our analysis
of differentMmp- and Panx1 null mouse lines illustrates how the
presence or absence of a phenotype (protection against lethal
endotoxemia) coincides with the presence or absence of one
passenger mutation, in casu mutant Casp11 derived from the
129 genome, and can produce ‘‘false-positive’’ phenotypes.Immunity 43, 200–209, July 21, 2015 ª2015 Elsevier Inc. 203
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Figure 3. Presence ofCasp11 Inactivating Passenger Mutation in 129 ESC-Derived Panx1Null Mice, but Not in C57BL/6 ESC-Derived Panx1-
Null Mice, Results in Resistance to LPS-Induced Shock
(A) Gel electrophoresis-separated PCR fragments of the genomic DNA region flanking the 5-bp deletion in Casp11 gene in Panx1 null mice.
(B) DNA sequencing profiles of the genomic DNA region flanking the 5-bp deletion in Casp11 gene in Panx1 null mice. C57BL/6 and 129 strains were used as
negative and positive controls, respectively, for the 5-bp deletion in Casp11.
(C and D) Survival and body temperature were analyzed in function of time after intraperitoneal injection of 15 mg kg-1 E. coli LPS in Panx1 null mice derived from
V.I.S.’s lab (Panx1Vsh/, n = 10), which carry the Casp11 passenger mutation, and matching wild-type controls (Panx1Vsh+/+, n = 8).
(E and F) Survival and body temperature were analyzed in function of time after intraperitoneal injection of 15 mg kg-1 E. coli LPS in Panx1 null mice derived from
V.M. Dixit’s lab (Panx1Vmd/, n = 5), which have a wild-type allele for Casp11, and matching wild-type controls (Panx1Vmd+/+, n = 5).)
(G and H) Survival and body temperature were analyzed in function of time after intraperitoneal injection of 15 mg kg-1 E. coli LPS in Casp11 null mice
(Casp11Vda/, n = 8) and matching wild-type controls (Casp11Vda+/+, n = 10). Survival was analyzed using Log rank (Mantel-Cox) test. Body temperature
curves were analyzed using F-test. *p < 0.05, ***p < 0.001, ****p < 0.0001. Error bars of body temperature represent SEM. See also Table S3.Validation of Two Predicted Protein Coding Variants in
129 Strain
Next, we selected one 129-derived indel (predicted as a ‘‘frame-
shift variant’’) in a gene involved in metabolism, viz. aldehyde ox-
idase 4 (Aox4) and one SNP (predicted as a ‘‘gained STOP’’) in a
gene involved in immune regulation viz. serine peptidase inhibi-
tor, clade A, member 3I (SerpinA3i). We confirmed the predicted
gained premature STOP codon in SerpinA3i (Figures S3A and
S3B) and T nucleotide insertion in Aox4 (Figure S4A), which
also results in a STOP codon after 11 codons (Figure S4B). For
a flanking region of 10 cM, the 129-derived SerpinA3i and
Aox4 passenger mutations could affect, respectively, 101 and
120 of the currently available 129-derived genetically modified
congenic mice (Figures S3C and S4C). For example, the Casp8
gene is %1cM distance from Aox4. We confirmed that the
commonly used 129-derived Casp8 conditionally deleted con-204 Immunity 43, 200–209, July 21, 2015 ª2015 Elsevier Inc.genic mouse line (Casp8Hed_FL/FL) contains this Aox4 inactivating
mutation, which is absent in C57BL/6JN-derived Casp8Tvb_FL/FL
mice (Figure S4A). These two validated case studies underscore
the strength of the genomic sequence released by Sanger Insti-
tute (Keane et al., 2011) and the associated protein-coding var-
iants predictions.
C57BL/6J and C57BL/6NJ Sub Strains Exhibit Opposing
Phenotypes after Lethal LPS Challenge
The International Mouse Phenotyping Consortium (IMPC) was
founded to avoid the effects of genetic background variation in
transgene technology (Austin et al., 2004; Skarnes et al., 2011).
The consortium intends to mutate all protein-coding genes in
the mouse using a combination of gene trapping and gene tar-
geting in C57BL/6 mouse ESCs instead of the previously used
129 ESCs. To date, this initiative has resulted in 29% of all
Figure 4. Susceptibility of C57BL/6 Sub-
strains J and NJ Show Significant Differ-
ence to LPS- and TNF-Induced Lethal
Shock
(A and B) Survival and body temperature were
analyzed in a function of time after intraperitoneal
injection of 10mg kg-1 E. coli LPS in C57BL/6J (n =
10) and C57BL/6NJ mice (n = 9). The combined
resultsof two independent experiments are shown.
(C and D) Survival and body temperature were
analyzed in function of time after intravenous in-
jection of 500 mg kg-1 TNF in C57BL/6J (n = 18) and
C57BL/6NJ mice (n = 16). The combined results of
two independent experiments are shown.
(E and F) Survival and body temperature were
analyzed in function of time after intraperitoneal
injection of 25mg kg-1 E. coli LPS in C57BL/6J (n =
9) and C57BL/6NJ mice (n = 5). Error bars of body
temperature represent SEM. **p < 0.01, ***p <
0.001, ****p<0.0001. Log rank (Mantel–Cox) test (B
and D) and F-test (A and C). See also Table S4.genetically modified mice that originate from IMPC (Figure 1D).
Importantly, the consortium uses ESCs derived from the
C57BL/6NJ mouse, which could be a problem because it was
separated from the commonly used inbred C57BL/6J strain 63
years ago. Indeed comparison of the genomes of these strains
(Mouse Genomes project [Keane et al., 2011]) revealed 34
SNPs and two indels (Simon et al., 2013). We confirmed these
two previously reported indels (Simon et al., 2013). However,
we predict 28 additional indels and 6 SNPs that result in an alter-
native or aberrant amino acid sequence (Table S4). To phenotyp-
ically compare the strains in the context of lethal shock, we re-
derived both C57BL/6NJ and C57BL/6J in our specific
pathogen free (SPF) facility by embryo transfer to circumvent
pathogenic background effects. In line with the previously re-
ported phenotypic differences between C57BL/6J and –NJ
(Simon et al., 2013), we found that C57BL/6NJ mice were signif-
icantly more resistant to lethal shock induced by LPS or TNF, as
shown by the survival rates (Figures 4A and 4C) and body tem-
perature (Figures 4B and 4D), indicating that even the small ge-
netic difference between the two C57Bl/6 strains is sufficient to
generate phenotypic differences in these experimental disease
models. Notably, this phenotypic difference between C57BL/6
sub strains in survival (Figure 4E) and hypothermia (Figure 4F)
faded out by using a supralethal dose of LPS (2.5 3 LD100).Immunity 43, 200–Web Tool to Identify Passenger
Mutation in Genetically Modified
Congenic Mice
To allow researchers to estimate the
impact of passenger mutations on their
particular genetically modified congenic
mice, we developed a passenger muta-
tion informatics search tool dubbed ‘‘Me-
PaMuFind-It’’ (http://me-pamufind-it.org)
that can easily verify the predicted identity
and number of passenger mutations in
129-derived genetically modified con-
genic mice. The tool generates the
following data sets: (1) a list of potentialpassenger mutations in the transgenic mouse of interest accord-
ing to the number of backcrosses, (2) the number and identity of
indels and SNPs that result in alternative or aberrant protein
expression (referred toasprotein coding variants), (3) list of genes
containing 129-derived untranslated region (UTR) and upstream
variants that affect the entered gene, (4) direct access to PubMed
reports on respective genes, (5) direct access to genetically
modified mouse lines reported in Mouse Genome Informatics,
and (6) a list of known genetically modified mouse lines affected
by a particular validated 129-derived passenger mutation. This
information permits to estimate the potential effect of particular
passenger mutations on the phenotype of the transgenic mice
of interest. Note that the functional effects ofmost predicted pas-
senger mutations are still unknown.
DISCUSSION
The importance of genetic background in genetically modified
congenic mice is generally well known. Typically, researchers
use littermate controls to deal with this issue, instead of wild-
type strain control (often C57BL/6mice). However, this approach
doesn’t solve the issue of 129-derived passenger mutations pre-
sent in the flanking regions of the target gene. In particular,
the flanking region of the target gene will originate from the209, July 21, 2015 ª2015 Elsevier Inc. 205
acceptor (which is often C57BL/6 strain) in the wild-type litter-
mate controls, while the region will originate from the donor
(which wasmostly 129-derived ESCs) in the genetically modified
littermates. The situation is different in case of conditional gene
modified mice. Because the target gene is flanked by two loxP
or Frt sites in all littermates, all mice equally carry the same pas-
senger mutations. Thus, the observed phenotypes in the Cre re-
combinase-expressing mice are likely due to the removal of the
gene of interest. However, investigators should include extra
control groups in their experimentalmodels such as theparticular
mouseCre line and/orCre recombinaseexpressingheterozygote
mice (geneFL/+ creTg/+) to exclude phenotypic interference from
the mouse Cre line. Of note, it is still possible that the observed
phenotype is influenced by the flanking 129-derived passenger
mutations.
What can be done to avoid this ‘‘spill over’’ of passenger mu-
tations? It is advised to construct transgenic mice on a pure ge-
netic background so that the resultingmice are ‘‘isogenic’’ rather
than congenic. Essentially, one should cross the obtained chi-
meras with mice with the same genetic background as the
ESCs used to generate transgenic mice. Essentially, the IMPC
was founded to avoid the effects of genetic background variation
in transgene technology and intends tomutate all protein-coding
genes in the mouse using a combination of gene trapping and
gene targeting in C57BL/6NJ mouse ESCs instead of the previ-
ously used 129 ESCs (Austin et al., 2004; Skarnes et al., 2011). In
addition, the EUCOMMTOOLS project is engineering 500 Cre
C57Bl/6NJ ESC lines to enable researchers to use transgenic
mice with a defined genetic background (Murray et al., 2012).
Alternatively, multiplex genome engineering technologies such
as CRISPR/Cas systems have also been widely introduced
(Cong et al., 2013; Jinek et al., 2012; Mali et al., 2013; Platt
et al., 2014), which will also help to circumvent problems associ-
ated with genetic background. Nevertheless, one has to be
cautious about nonspecific integration often associated with
CRISPR/Cas genome editing, which are currently minimized by
using optimized adapted methods (Shen et al., 2014).
Our finding that nearly all 129-derived genetically modified
congenic mice contain multiple passenger mutations despite
intensive backcrossing implies that the phenotypes observed
in these mice might be due to flanking passenger mutations
rather than the defect in the targeted gene. Considering that
almost 8,000 different genetically modified congenic mice are
populated with 129-derived passenger mutations, it will be a
challenge to elucidate the causative link between the targeted
gene and the observed phenotypes. We exemplify this in
the current study using the recently identified 129-derived
Casp11 passenger mutation, which potentially affects 86 genet-
ically modified congenic mice (Tables S3 and S4). We show
that 129-derived genetically modified congenic mice targeting
some MMP family members and PANX1 are affected by this
129-derived Casp11 inactivating mutation, which consequently
provides these mice resistance to LPS. Basically, in case that
the passenger mutation interferes with the experimental model,
there is a risk of false positive phenotypes. Of the 1084 genes
predicted to be aberrantly expressed in 129 mice, we selected
and validated two protein coding variants involved inmetabolism
and immune regulation viz. Aox4 and SerpinA3i. Considering
that SERPINA3 inhibits cathepsin G released by activated neu-206 Immunity 43, 200–209, July 21, 2015 ª2015 Elsevier Inc.trophils (Heit et al., 2013), one can expect phenotypic immuno-
logical inference of SERPINA3 inactivation in the 101 reported
129 ESC-derived genetically modified mouse lines of which the
targeted gene flanks the SerpinA3i locus. In an attempt to link
the Aox4 passenger mutation to a phenotype observed in genet-
ically modified congenic mice targeting an Aox4-neighboring
gene, we found that mice deficient in phospholipase Cε (PLCε)
showed a similar thickening of the epidermis (Martins et al.,
2014) as observed in Aox4 null mice (Terao et al., 2009). This
epidermal thickening in the PLCε-deficient mice is potentially
due to the 129-derived Aox4 passenger mutation.
Several reports have identified 129-derived protein coding
variants in for example DAP12 (Tyrobp) signaling (McVicar
et al., 2002), DNA polymerase iota (Poli) (McDonald et al.,
2003), beaded filament structural protein 2 (Bfsp2) (Alizadeh
et al., 2004; Sandilands et al., 2004), disrupted-in-schizophrenia
(Disc1) (Go´mez-Sintes et al., 2014; Koike et al., 2006), apolipo-
protein A-II (Apoa2) (Su et al., 2009), oculocutaneous albinism
II (Oca2) (Rogers et al., 2012), and chromatin licensing and
DNA replication factor 1 (Cdt1) (Coulombe et al., 2013). The
129-derived protein coding variant in Bfsp2 and Apoa2, respec-
tively, results in defects in the lens (Sandilands et al., 2004) and
high density lipoprotein (HDL) metabolism (Su et al., 2009).
Considering genetically modified congenic mice that target
genes that flank (%10 cM) the two variants, we found genetically
modified mouse lines reported with similar phenotypes that
might be due to the passenger rather than the targeted gene it-
self. For example, in case of Apoa2, we found genetically modi-
fied mouse lines targeting 11b-Hydroxy-steroid dehydrogenase
type 1, which show increased HDL amounts (Morton et al., 2001)
and TLR5, which have increased adiposity (Vijay-Kumar et al.,
2010). In case of Bfsp2, we found genetically modified mouse
lines targeting gluthation peroxidase 1 (Spector et al., 1998;
Spector et al., 1996) and aB-crystallin (Brady et al., 2001).
It is important that the scientific community becomes more
aware of thebroad impact of passengermutations that affect phe-
notypes of mice in a wide variety of experimental disease models
and fundamental biological studies. In summary,with 1,084 genes
predicted tobeaberrantly expressed in129mice, our casestudies
reveal a highly underestimated issue of false-positive results using
genetically modified congenic mouse lines. Our comparative
genomic analysis predicts that nearly all 129-derived genetically
modified congenic mice are affected bymultiple inactivating pas-
senger mutations despite intensive backcrossing to C57BL/6
mice. This implies that the phenotypes of most of these congenic
mouse lines, and cells derived of thesemice, may be heavily influ-
enced by inactivating passenger mutations in the flanking regions
of the targeted genes. Consequently, phenotypic studies using
primary mouse embryonic fibroblasts, bone-marrow-derived
macrophages, or lymphocytes derived from 129-derived geneti-
cally modified congenic mice are equally affected by these pas-
senger mutations. We believe that the variable translatability of
the results of mouse studies to humans might be partially due to
the phenotypic interference of passenger mutations (Osuchowski
et al., 2014). TheMe-PaMuFind-It web toolwill help researchers to
estimate the number and effect of passenger mutations in their
transgenic mice and to decide whether to regenerate them in a
defined genetic background, e.g., via IMPC or using genome en-
gineering technologies such as CRISPR/Cas.
EXPERIMENTAL PROCEDURES
Bioinformatics and Comparative Genome Analyses
We analyzed the SNP data release v3 (REL-1303-SNPs_Indels-GRCm238)
from the Mouse Genome Project available at Sanger Institute (ftp://
ftp-mouse.sanger.ac.uk/REL-1303-SNPs_Indels-GRCm38/; Keane et al.,
2011). The data in the indel vcf file (mgp.v3.indels.rsIDdbSNPv137.vcf) and
SNP vcf file (mgp.v3.snps.rsIDdbSNPv137.vcf) were filtered to retrieve indels
and SNPs present in at least one of the three 129 strains (129P2/OlaH, 129S1/
SvIm and 129S5SvEvB) and affecting the protein coding sequence of the
genes. These so-called protein coding variants are based on the following
sequence ontology (SO) terms: stop_gained, stop_lost, inframe_insertion, in-
frame_deletion, frameshift_variant, splice_donor_variant, splice_acceptor_
variant, and coding_sequence_variant. In total, 949 indels and 446 SNPs
affecting 1,084 mouse genes were retained. We gathered chromosome and
gene start and end positions for 1,084 genes covering 1,395 variations (949
indels + 446 SNPs). The Ensembl gene ID (ENSMUSG) was used to find the
most upstream and downstream start and stop in all Ensembl transcripts (EN-
SMUST) for that gene and saved as gene start and end. Next these genome
coordinates were used to search for flanking genes within 2, 10, and 20
Mbps both upstream and downstream. We then downloaded all mouse
phenotypic allele data from the MGI resource (ftp://ftp.informatics.jax.org)
and extracted the data of genetically modified mouse lines. Information on
5,322 genes (corresponding to 7,979 129-derived genetically modified mouse
lines) was connected to genes with passenger mutations and affected genes.
Additionally we filtered the data for 5 kb upstream, 50 UTR and 30 UTR indels
and SNPs to identify putative regulatory variants. This analysis retrieved in total
673,023 regulatory variants, which are listed separately for a gene of interest.
All data were stored in a MySQL database and can be queried using the pub-
licly available web tool Me-PaMuFind-It.
Development of the Me-PaMuFind-It Web Tool
It is important for scientists to easily check whether a 129-derived transgenic
mousemight carry passenger mutations. We developed the web tool ‘‘Me-Pa-
MuFind-It’’ (http://me-pamufind-it.org), which generates a list of the potential
passenger mutations present in any 129-derived transgenic mouse.
To start a search with Me-PaMuFind-It, the user enters a gene symbol or
database accession number and chooses the number of backcrosses. The
user will then be given three main types of information. The upper panel gives
the user more information about the gene itself. With one click the user can ac-
cess the NCBI Entrez Gene page, Ensembl Gene Page, all the PubMed articles
about the gene, detailed information about protein coding variants and puta-
tive regulatory variants of the gene in the three 129 strains, and detailed infor-
mation on the available genetically depleted mice.
Most important, the middle panel shows all the protein coding variants in
flanking genes that can influence the gene of interest. To get a better overview
of the distance between these flanking genes and the gene of interest, we
incorporated a ‘‘Visualize’’ function. This function shows a genomic map of
10 cM upstream and downstream of the gene, but the user can also visualize
the 2 cM and 20 cM region. The user can start a Me-PaMuFind-It search of
every gene in this genomicmap simply by clicking on the gene. As the genomic
sequence is available for three 129 substrains (129P2/OlaH, 129S1/SvIm and
129S5SvEvB), we indicated for every variant, which 129 strain is affected.
Furthermore, the user can analyze the variant sequence with a click. Finally,
we also incorporated a link to UCSC to enable the user to analyze the variant
sequence in more detail.
If the gene of interest carries any protein coding variant, the lower panel lists
all the genes that might be affected by this variant. The distance between the
affected genes and the gene of interest is again indicated by percentages.
Every gene mentioned in the Me-PaMuFind-It tool indicates whether a genet-
ically depleted mouse exists. Additionally, the user can get detailed informa-
tion about the genetically depleted mouse, such as the genetic background
of the genetically depleted or the name of the lab that generated it. Finally,
there is also a link to the Mouse Genome Informatics website.
Mice
All the mice were bred under specific-pathogen-free (SPF) conditions, unless
indicated differently. Mice were housed in temperature-controlled, air-condi-tioned facilities with subsequent 14 hr light and 10 hr dark cycles, and food
and water ad libitum, and were used at the age of 8–12 weeks. Sex- and
age-matched animals were used in all experiments, which were approved
by the animal ethics committee of Ghent University.
129S1/SvImJ mice (002448) were purchased from The Jackson Laboratory.
C57BL/6J. C57BL/6Nmice were purchased from The Jackson Laboratory and
re-derived in our SPF animal facility. Panx1 null mice generated using 129-
derived (MGI:5487761) andC57BL/6-derived ESCs (MGI:5013648) were kindly
provided by the V.I.S. and Dixit labs, respectively. Mmp8 (MGI:2681103),
Mmp13Cli (MGI:3521852) and Mmp19 null mice (MGI:3505589) were
kindly provided by Dr. Carloz Lopez-Otin (Universidad de Oviedo, Spain).
Mmp3 (MGI:2386262), Mmp7 (MGI:1857932), Mmp9 (MGI:1932294), and
Mmp13Ebb null mice (MGI:3521852) were kindly provided, respectively, by
Dr. John S. Mudget (Merck Research Laboratories, USA), Dr. Carole L. Wilson
(Medical University of SouthCarolina,USA), Dr. StevenD. Shapiro (Washington
University School of Medicine, USA), and Dr. Edward B. Brown (University of
Rochester, USA). The Mmp13Cli and Mmp13Ebb null mice (MGI:3521852)
both originated from Stephen M. Krane’s lab (Harvard Medical School and
Massachusetts General Hospital, USA). Mmp9 and -19 null mice were bred
in our conventional mouse facility. The mice that were imported from USA
(Mmp13Ebb null mice from Brown’s lab, and Panx1 null mice from V.I.S. and
Dixit labs) hadbeenbred underSPFconditions in the respective labs and trans-
ferred to our conventional mouse facility in individual ventilated cages for LPS
lethality studies.
Mouse Genomic DNA and Genotyping
Mouse genomic DNA prepared from mouse tails, unless indicated differently,
was donated by the following persons:Mmp28 null mice, Dr. Anne Manicone,
(University of Washington, USA); Mmp9 null mice, Dr. Anna Rosell (Institut de
Recerca Hospital Vall d’Hebron, Barcelona); Mmp14 null mice, Dr. Paola
Zigrino (University of Cologne, Germany); Mmp7 null mice, Dr. Sarah Jane
George (School of Clinical Sciences, UK); Mmp3 null mice, Dr. Ranjan Gupta
(University of California, USA); Mmp19 null mice, Dr. Annie Pardo (Ciudad
Universitaria, Mexico); and Mmp13Ebb null mice, Dr. Seth Perry (University of
Rochester, USA). Genomic DNA was prepared locally from mouse tails of
Mmp8 null mice bred in house, and from frozen sperm of Mmp13Cli null mice
stored in house.
The Casp11 inactivating passenger mutation was identified by PCR using
primers 50-AGGCATATCTATAATCCCTTCACTG-30 and 50-GGAATATATCAAA
GAGATGACAAGAGC-30. Temperature scheme standard PCR: 4 min 94C,
1 min 94C, 0.5 min 58C, 1 min 72C, 7 min 72C, and end at 12C. Samples
were loaded on 3% agarose gel, and the 5 bp-deletion Casp11 fragment runs
slightly higher than the wild-type fragment at a high of approximately 220 bp. In
addition, the 5-bp deletion (Casp11 inactivation) was confirmed by sequencing
a PCR product using primers 50-CAGTATTATTATTGGTGATGCAAATG-30 and
50-GGAATATATCAAAGAGATGACAAGAGC-30.
Reagents and Injections
Mice were injected intraperitoneally (i.p.) with the indicated dose of LPS from
Escherichia coli O111:B4 (cat no: L-2630, Sigma-Aldrich) or Salmonella enter-
ica serotype abortus equi (cat no: L-5886, Sigma-Aldrich) suspended in LPS-
free PBS. Mice were injected intravenously (i.v.) with the indicated dose of
TNF (purified in house) suspended in LPS-free PBS.
Statistics
All statistics were performed using Prism software (GraphPad Software) or
Genstat (Payne et al. Genstat Release 16.1 Reference Manual, Part 3. VSN In-
ternational). All experiments were set up as a completely randomized design.
Survival curves were compared with a Mantel-Cox test. We used restricted
maximum likelihood (REML) as implemented in Genstat (Payne et al. Genstat
Release 16.1 Reference Manual, Part 3. VSN International) to perform the
repeated-measurements analysis for body temperature. Repeated-measure-
ments data were analyzed by fitting the following linear mixed model (random
terms underlined): yijrt = m + genotypei + timet + genotype.timeit + experimentr +
subjectijr + subject.timeijrt, where yijrt is the body temperature of the jth individ-
ual of genotype i, measured in the rth experiment at time point t. The random
term subject.time was used as residual termwith correlation structure. Various
ways of modeling the correlation structure (unstructured, antedependenceImmunity 43, 200–209, July 21, 2015 ª2015 Elsevier Inc. 207
order 1 and 2, power model [city block metric]) were compared in the residual
maximum likelihood (REML) framework, with time points set as not equally
spaced. Selection of the best model fit was based on a likelihood ratio test
(LRT) statistic and/or the Aikake Information coefficient (AIC). When residuals
from the analysis indicated increasing variance over time, this was modeled
directly by specifying that heterogeneity is to be introduced into the model.
Significance of the fixed main and interaction effects was assessed by an F
test.
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011.
AUTHOR CONTRIBUTIONS
T.V.B. and P.V. designed the research and wrote the paper. T.V.B. carried out
experiments and analyzed the data. C.L. assisted with research design, data
interpretation, and writing of the paper. P.H. and L.M. performed bioinformatic
analyses and developed the Me-PaMuFind-It web tool. R.E.V., I.B., T.D.,
E.V.W. and S.M.C carried out experiments. S.W.P. and V.I.S provided
Mmp13- and Panx1-null mice, respectively, and assisted in the writing of the
paper. M.V. performed statistics.
ACKNOWLEDGMENTS
We thank Wim Declercq for critical reading and feedback. We are grateful to
Edward B. Brown for providing us Mmp13-null mice and to Vishva M. Dixit
and Genentech for the Panx1-null mice. T.V.B. is paid by a research grant
from the Foundation against Cancer (2012-188) and his research is supported
by the Methusalem grant to P.V. Research in P.V.’s unit is further supported by
European grants (FP6 ApopTrain, MRTNCT-035624; FP7 EC RTD Integrated
Project, Apo-Sys, FP7-200767; Euregional PACT II), Belgian grants (Interuni-
versity Attraction Poles, IAP 6/18, IAP 7/32), Flemish grants (Research Foun-
dation Flanders [FWO G.0875.11, FWO G.0973.11 N, FWO G.0A45.12 N,
FWO G.0172.12, FWO G.0787.13N, G0C3114N, and FWO KAN 31528711]
and Foundation against Cancer [2012-188]), Ghent University grants (MRP,
GROUP-ID consortium), and grants from Flanders Institute for Biotechnology
(VIB). P.V. holds a Methusalem grant (BOF09/01M00709) from the Flemish
Government. V.I.S. holds a NIH R01 grant EY021517 from, USA. R.E.V. is a
Dr. Assistant at Ghent University and researcher in the lab of C.L. and is sup-
ported by FWO and Ghent University grants.
Received: February 4, 2015
Revised: April 9, 2015
Accepted: June 11, 2015
Published: July 7, 2015
REFERENCES
Alizadeh, A., Clark, J., Seeberger, T., Hess, J., Blankenship, T., and FitzGerald,
P.G. (2004). Characterization of a mutation in the lens-specific CP49 in the 129
strain of mouse. Invest. Ophthalmol. Vis. Sci. 45, 884–891.
Austin, C.P., Battey, J.F., Bradley, A., Bucan, M., Capecchi, M., Collins, F.S.,
Dove, W.F., Duyk, G., Dymecki, S., Eppig, J.T., et al. (2004). The knockout
mouse project. Nat. Genet. 36, 921–924.
Brady, J.P., Garland, D.L., Green, D.E., Tamm, E.R., Giblin, F.J., and
Wawrousek, E.F. (2001). AlphaB-crystallin in lens development and muscle
integrity: a gene knockout approach. Invest. Ophthalmol. Vis. Sci. 42, 2924–
2934.
Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X.,
Jiang,W., Marraffini, L.A., and Zhang, F. (2013). Multiplex genome engineering
using CRISPR/Cas systems. Science 339, 819–823.
Coulombe, P., Gre´goire, D., Tsanov, N., and Me´chali, M. (2013). A sponta-
neous Cdt1 mutation in 129 mouse strains reveals a regulatory domain re-
straining replication licensing. Nat. Commun. 4, 2065.208 Immunity 43, 200–209, July 21, 2015 ª2015 Elsevier Inc.Crawley, J.N., Belknap, J.K., Collins, A., Crabbe, J.C., Frankel, W., Henderson,
N., Hitzemann, R.J., Maxson, S.C., Miner, L.L., Silva, A.J., et al. (1997).
Behavioral phenotypes of inbred mouse strains: implications and recommen-
dations for molecular studies. Psychopharmacology (Berl.) 132, 107–124.
Flaherty, L. (1981). Congenic Strains, Volume 1 (N.Y: Academic Press).
Gerlai, R. (1996). Gene-targeting studies of mammalian behavior: is it the mu-
tation or the background genotype? Trends Neurosci. 19, 177–181.
Go´mez-Sintes, R., Kvajo, M., Gogos, J.A., and Lucas, J.J. (2014). Mice with a
naturally occurring DISC1 mutation display a broad spectrum of behaviors
associated to psychiatric disorders. Front. Behav. Neurosci. 8, 253.
Hagar, J.A., Powell, D.A., Aachoui, Y., Ernst, R.K., and Miao, E.A. (2013).
Cytoplasmic LPS activates caspase-11: implications in TLR4-independent
endotoxic shock. Science 341, 1250–1253.
Heit, C., Jackson, B.C., McAndrews, M., Wright, M.W., Thompson, D.C.,
Silverman, G.A., Nebert, D.W., and Vasiliou, V. (2013). Update of the human
and mouse SERPIN gene superfamily. Hum. Genomics 7, 22.
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A., and Charpentier,
E. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive
bacterial immunity. Science 337, 816–821.
Kanneganti, T.D., Lamkanfi, M., Kim, Y.G., Chen, G., Park, J.H., Franchi, L.,
Vandenabeele, P., and Nu´n˜ez, G. (2007). Pannexin-1-mediated recognition
of bacterial molecules activates the cryopyrin inflammasome independent of
Toll-like receptor signaling. Immunity 26, 433–443.
Kayagaki, N., Warming, S., Lamkanfi, M., Vande Walle, L., Louie, S., Dong, J.,
Newton, K., Qu, Y., Liu, J., Heldens, S., et al. (2011). Non-canonical inflamma-
some activation targets caspase-11. Nature 479, 117–121.
Keane, T.M., Goodstadt, L., Danecek, P., White, M.A., Wong, K., Yalcin, B.,
Heger, A., Agam, A., Slater, G., Goodson, M., et al. (2011). Mouse genomic
variation and its effect on phenotypes and gene regulation. Nature 477,
289–294.
Kenneth, N.S., Younger, J.M., Hughes, E.D., Marcotte, D., Barker, P.A.,
Saunders, T.L., and Duckett, C.S. (2012). An inactivating caspase 11 passen-
ger mutation originating from the 129murine strain in mice targeted for c-IAP1.
Biochem. J. 443, 355–359.
Koike, H., Arguello, P.A., Kvajo, M., Karayiorgou, M., and Gogos, J.A. (2006).
Disc1 is mutated in the 129S6/SvEv strain and modulates working memory in
mice. Proc. Natl. Acad. Sci. USA 103, 3693–3697.
Lusis, A.J., Yu, J., and Wang, S.S. (2007). The problem of passenger genes in
transgenic mice. Arterioscler. Thromb. Vasc. Biol. 27, 2100–2103.
Mali, P., Yang, L., Esvelt, K.M., Aach, J., Guell, M., DiCarlo, J.E., Norville, J.E.,
and Church, G.M. (2013). RNA-guided human genome engineering via Cas9.
Science 339, 823–826.
Mariathasan, S., Weiss, D.S., Newton, K., McBride, J., O’Rourke, K., Roose-
Girma, M., Lee, W.P., Weinrauch, Y., Monack, D.M., and Dixit, V.M. (2006).
Cryopyrin activates the inflammasome in response to toxins and ATP.
Nature 440, 228–232.
Martins, M., McCarthy, A., Baxendale, R., Guichard, S., Magno, L., Kessaris,
N., El-Bahrawy, M., Yu, P., and Katan, M. (2014). Tumor suppressor role of
phospholipase C epsilon in Ras-triggered cancers. Proc. Natl. Acad. Sci.
USA 111, 4239–4244.
McDonald, J.P., Frank, E.G., Plosky, B.S., Rogozin, I.B., Masutani, C.,
Hanaoka, F., Woodgate, R., and Gearhart, P.J. (2003). 129-derived strains of
mice are deficient in DNA polymerase iota and have normal immunoglobulin
hypermutation. J. Exp. Med. 198, 635–643.
McVicar, D.W., Winkler-Pickett, R., Taylor, L.S., Makrigiannis, A., Bennett, M.,
Anderson, S.K., and Ortaldo, J.R. (2002). Aberrant DAP12 signaling in the 129
strain of mice: implications for the analysis of gene-targeted mice. J. Immunol.
169, 1721–1728.
Morton, N.M., Holmes, M.C., Fie´vet, C., Staels, B., Tailleux, A., Mullins, J.J.,
and Seckl, J.R. (2001). Improved lipid and lipoprotein profile, hepatic insulin
sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase
type 1 null mice. J. Biol. Chem. 276, 41293–41300.
Murray, S.A., Eppig, J.T., Smedley, D., Simpson, E.M., and Rosenthal, N.
(2012). Beyond knockouts: cre resources for conditional mutagenesis.
Mamm. Genome 23, 587–599.
Osuchowski, M.F., Remick, D.G., Lederer, J.A., Lang, C.H., Aasen, A.O.,
Aibiki, M., Azevedo, L.C., Bahrami, S., Boros, M., Cooney, R., et al. (2014).
Abandon the mouse research ship? Not just yet! Shock 41, 463–475.
Platt, R.J., Chen, S., Zhou, Y., Yim, M.J., Swiech, L., Kempton, H.R., Dahlman,
J.E., Parnas, O., Eisenhaure, T.M., Jovanovic, M., et al. (2014). CRISPR-Cas9
knockin mice for genome editing and cancer modeling. Cell 159, 440–455.
Rogers, M.S., Boyartchuk, V., Rohan, R.M., Birsner, A.E., Dietrich, W.F., and
D’Amato, R.J. (2012). The classical pink-eyed dilution mutation affects angio-
genic responsiveness. PLoS ONE 7, e35237.
Saleh, M., Mathison, J.C., Wolinski, M.K., Bensinger, S.J., Fitzgerald, P.,
Droin, N., Ulevitch, R.J., Green, D.R., and Nicholson, D.W. (2006). Enhanced
bacterial clearance and sepsis resistance in caspase-12-deficient mice.
Nature 440, 1064–1068.
Sandilands, A., Wang, X., Hutcheson, A.M., James, J., Prescott, A.R.,
Wegener, A., Pekny, M., Gong, X., and Quinlan, R.A. (2004). Bfsp2 mutation
found in mouse 129 strains causes the loss of CP490 and induces vimentin-
dependent changes in the lens fibre cell cytoskeleton. Exp. Eye Res. 78,
875–889.
Shen, B., Zhang, W., Zhang, J., Zhou, J., Wang, J., Chen, L., Wang, L.,
Hodgkins, A., Iyer, V., Huang, X., and Skarnes, W.C. (2014). Efficient genome
modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat.
Methods 11, 399–402.
Simon, M.M., Greenaway, S., White, J.K., Fuchs, H., Gailus-Durner, V., Wells,
S., Sorg, T., Wong, K., Bedu, E., Cartwright, E.J., et al. (2013). A comparative
phenotypic and genomic analysis of C57BL/6J and C57BL/6N mouse strains.
Genome Biol. 14, R82.
Simpson, E.M., Linder, C.C., Sargent, E.E., Davisson, M.T., Mobraaten, L.E.,
and Sharp, J.J. (1997). Genetic variation among 129 substrains and its impor-
tance for targeted mutagenesis in mice. Nat. Genet. 16, 19–27.
Skarnes, W.C., Rosen, B., West, A.P., Koutsourakis, M., Bushell, W., Iyer, V.,
Mujica, A.O., Thomas, M., Harrow, J., Cox, T., et al. (2011). A conditional
knockout resource for the genome-wide study of mouse gene function.
Nature 474, 337–342.
Spector, A., Yang, Y., Ho, Y.S., Magnenat, J.L., Wang, R.R., Ma, W., and Li,
W.C. (1996). Variation in cellular glutathione peroxidase activity in lens epithe-
lial cells, transgenics and knockouts does not significantly change the
response to H2O2 stress. Exp. Eye Res. 62, 521–540.
Spector, A., Kuszak, J.R., Ma, W., Wang, R.R., Ho, Ys., and Yang, Y. (1998).
The effect of photochemical stress upon the lenses of normal and glutathione
peroxidase-1 knockout mice. Exp. Eye Res. 67, 457–471.Su, Z., Wang, X., Tsaih, S.W., Zhang, A., Cox, A., Sheehan, S., and Paigen, B.
(2009). Genetic basis of HDL variation in 129/SvImJ and C57BL/6J mice:
importance of testing candidate genes in targeted mutant mice. J. Lipid Res.
50, 116–125.
Terao, M., Kurosaki, M., Barzago, M.M., Fratelli, M., Bagnati, R., Bastone, A.,
Giudice, C., Scanziani, E., Mancuso, A., Tiveron, C., and Garattini, E. (2009).
Role of the molybdoflavoenzyme aldehyde oxidase homolog 2 in the biosyn-
thesis of retinoic acid: generation and characterization of a knockout mouse.
Mol. Cell. Biol. 29, 357–377.
Vanden Berghe, T., Goethals, A., Demon, D., Bogaert, P., Mak, T.W., Cauwels,
A., and Vandenabeele, P. (2013). An inactivating caspase-11 passenger muta-
tion muddles sepsis research. Am. J. Respir. Crit. Care Med. 188, 120–121.
Vandenbroucke, R.E., and Libert, C. (2014). Is there new hope for therapeutic
matrix metalloproteinase inhibition? Nat. Rev. Drug Discov. 13, 904–927.
Vandenbroucke, R.E., Dejonckheere, E., Van Lint, P., Demeestere, D., Van
Wonterghem, E., Vanlaere, I., Puime`ge, L., Van Hauwermeiren, F., De
Rycke, R., Mc Guire, C., et al. (2012). Matrix metalloprotease 8-dependent
extracellular matrix cleavage at the blood-CSF barrier contributes to lethality
during systemic inflammatory diseases. J. Neurosci. 32, 9805–9816.
Vandenbroucke, R.E., Dejonckheere, E., Van Hauwermeiren, F., Lodens, S.,
De Rycke, R., Van Wonterghem, E., Staes, A., Gevaert, K., Lo´pez-Otin, C.,
and Libert, C. (2013). Matrix metalloproteinase 13 modulates intestinal epithe-
lial barrier integrity in inflammatory diseases by activating TNF. EMBO Mol.
Med. 5, 932–948.
Vandenbroucke, R.E., Vanlaere, I., Van Hauwermeiren, F., Van Wonterghem,
E., Wilson, C., and Libert, C. (2014). Pro-inflammatory effects of matrix metal-
loproteinase 7 in acute inflammation. Mucosal Immunol. 7, 579–588.
Vanlaere, I., and Libert, C. (2009). Matrix metalloproteinases as drug targets in
infections caused by gram-negative bacteria and in septic shock. Clin.
Microbiol. Rev. 22, 224–239.
Vijay-Kumar, M., Aitken, J.D., Carvalho, F.A., Cullender, T.C., Mwangi, S.,
Srinivasan, S., Sitaraman, S.V., Knight, R., Ley, R.E., and Gewirtz, A.T.
(2010). Metabolic syndrome and altered gut microbiota in mice lacking Toll-
like receptor 5. Science 328, 228–231.
Wang, S., Miura, M., Jung, Y.K., Zhu, H., Li, E., and Yuan, J. (1998). Murine
caspase-11, an ICE-interacting protease, is essential for the activation of
ICE. Cell 92, 501–509.
Yalcin, B., Wong, K., Agam, A., Goodson, M., Keane, T.M., Gan, X., Nella˚ker,
C., Goodstadt, L., Nicod, J., Bhomra, A., et al. (2011). Sequence-based char-
acterization of structural variation in the mouse genome. Nature 477, 326–329.Immunity 43, 200–209, July 21, 2015 ª2015 Elsevier Inc. 209
